Who are Wave Life Sciences Ltd.'s main suppliers?

Wave Life Sciences Ltd. (WVE) key suppliers include: GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3, GLAXO-GROUP-LIMITED, SHIN-NIPPON-BIOMEDICAL-LABORATORIES-LTD, Dyne Therapeutics, Inc., Entrada Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/WVE.

Who are Wave Life Sciences Ltd.'s major customers?

Wave Life Sciences Ltd. (WVE) key customers include: Dyne Therapeutics, Inc., iBio, Inc., Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company Limited, Entrada Therapeutics, Inc.. View the full customer network at chainsifter.com/chain/WVE.

What sector is Wave Life Sciences Ltd. in?

Wave Life Sciences Ltd. (WVE) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

WVE Supply Chain: Wave Life Sciences Ltd. Supplier List & 13 Relationships

5Suppliers

5Customers

3Debt Items

20Related Chains

Wave Life Sciences Ltd. Suppliers

Ticker	Name	Confidence	Evidence
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3	GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3	90%	Pursuant to the GSK Collaboration Agreement, we and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics.
GLAXO-GROUP-LIMITED	GLAXO-GROUP-LIMITED	85%	With respect to the $50.0 million equity investment, on December 13, 2022, we entered into a Share Purchase Agreement (the "GSK Share Purchase Agreement") with Glaxo Group Limited ("GGL"), an affilia…
SHIN-NIPPON-BIOMEDICAL-LABORATORIES-LTD	SHIN-NIPPON-BIOMEDICAL-LABORATORIES-LTD	80%	Pursuant to the terms of various contract research service agreements with SNBL, a contract research organization and one of our shareholders, and its affiliates, we paid SNBL $4.0 million from Janua…
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph:…
TRDA	Entrada Therapeutics, Inc.	72%	Reciprocal relationship from TRDA graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TRDA gra…

Wave Life Sciences Ltd. Customers

Ticker	Name	Confidence	Evidence
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrup…
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Biosc…
TKPHF	Takeda Pharmaceutical Company Limited	72%	hich would increase the number of programs available to both parties. The Company will lead all preclinical research for GSK and the Company’s collaboration programs up to investigational new drug (“…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from WVE graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from WVE graph: hich would increase the number of p…
TRDA	Entrada Therapeutics, Inc.	72%	Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub…

Wave Life Sciences Ltd. Debt Obligations

Instrument	Description	Confidence	Evidence
WVE-DEBT-13625	Warrants outstanding: 46938000	90%	xbrl warrant detail from xbrl 2025-12-31.
WVE-DEBT-13626	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2015-12-31.
WVE-DEBT	Debt stack $15.7M	90%	Market cache reports total debt of $15.7M.

Wave Life Sciences Ltd. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Wave Life Sciences Ltd..

Wave Life Sciences Ltd. Ownership

Holder	Name	Confidence	Evidence
WVE-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 237 tracked holders.

Wave Life Sciences Ltd. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
KRYS	Krystal Biotech, Inc.	100.00	2
SLDB	Solid Biosciences Inc.	100.00	2
KRRO	Korro Bio, Inc.	100.00	2
TRDA	Entrada Therapeutics, Inc.	100.00	1	['customer', 'supplier']
MYGN	Myriad Genetics, Inc.	100.00	2
SRRK	Scholar Rock Holding Corporation	100.00	2
IBIO	iBio, Inc.	100.00	1	['customer']
TKPHF	Takeda Pharmaceutical Company Limited	100.00	1	['customer']
BEAM	Beam Therapeutics Inc.	100.00	2
HTGC	Hercules Capital, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
BMRN	BioMarin Pharmaceutical Inc.	100.00	2
SRPT	Sarepta Therapeutics, Inc.	100.00	2
ARWR	Arrowhead Pharmaceuticals, Inc.	100.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	100.00	2
HRMY	Harmony Biosciences Holdings, Inc.	100.00	2
GRFS	Grifols, S.A.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	1	['customer', 'supplier']
RNA	Atrium Therapeutics, Inc.	100.00	2

Wave Life Sciences Ltd. Supply Chain